FDA Approves First All-Oral AML Regimen as Inqovi Plus Venetoclax Clears for Patients Ineligible for Intensive Chemotherapy
The FDA on May 13 cleared Taiho Oncology's Inqovi combined with venetoclax as the first fully oral treatment for older or unfit AML patients, replacing injection-based clinic visits.
5 min read7 sources